Management and outcome of patients with chronic myeloid
leukemia in blast phase in the tyrosine kinase inhibitor era -
analysis of the European LeukemiaNet Blast Phase Registry

J 2024

Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry

BRIOLI, Annamaria, Elza LOMAIA, Christian FABISCH, Tomasz SACHA, Hana KLAMOVA et. al.

Základní údaje

Originální název

Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry

Autoři

BRIOLI, Annamaria, Elza LOMAIA, Christian FABISCH, Tomasz SACHA, Hana KLAMOVA, Elena MOROZOVA, Aleksandra GOLOS, Philipp ERNST, Ulla OLSSON-STROMBERG, Daniela ŽÁČKOVÁ (203 Česká republika, domácí), Franck E NICOLINI, Han BAO, Fausto CASTAGNETTI, Elzbieta PATKOWSKA, Jiří MAYER (203 Česká republika, domácí), Klaus HIRSCHBUEHL, Helena PODGORNIK, Edyta PACZKOWSKA, Anne PARRY, Thomas ERNST, Astghik VOSKANYAN, Elzbieta SZCZEPANEK, Susanne SAUSSELE, Georg-Nikolaus FRANKE, Alexander KIANI, Edgar FABER, Stefan KRAUSE, Luis Felipe CASADO, Krzysztof LEWANDOWSKI, Matthias EDER, Peter ANHUT, Justyna GIL, Thomas SUEDHOFF, Holger HEBART, Sonja HEIBL, Markus PFIRRMANN, Andreas HOCHHAUS a Michael LAUSEKER

Vydání

Leukemia, London, Nature Publishing Group, 2024, 0887-6924

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 11.400 v roce 2022

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1038/s41375-024-02204-y

UT WoS

001194843700001

Klíčová slova anglicky

chronic myeloid leukemia; tyrosine kinase inhibitor era

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 7. 2024 13:39, Mgr. Tereza Miškechová

Anotace

V originále

Blast phase (BP) of chronic myeloid leukemia (CML) still represents an unmet clinical need with a dismal prognosis. Due to the rarity of the condition and the heterogeneity of the biology and clinical presentation, prospective trials and concise treatment recommendations are lacking. Here we present the analysis of the European LeukemiaNet Blast Phase Registry, an international collection of the clinical presentation, treatment and outcome of blast phases which had been diagnosed in CML patients after 2015. Data reveal the expected heterogeneity of the entity, lacking a clear treatment standard. Outcomes remain dismal, with a median overall survival of 23.8 months (median follow up 27.8 months). Allogeneic stem cell transplantation (alloSCT) increases the rate of deep molecular responses. De novo BP and BP evolving from a previous CML do show slightly different features, suggesting a different biology between the two entities. Data show that outside clinical trials and in a real-world setting treatment of blast phase is individualized according to disease- and patient-related characteristics, with the aim of blast clearance prior to allogeneic stem cell transplantation. AlloSCT should be offered to all patients eligible for this procedure.

Citovat

BRIOLI, Annamaria, Elza LOMAIA, Christian FABISCH, Tomasz SACHA, Hana KLAMOVA, Elena MOROZOVA, Aleksandra GOLOS, Philipp ERNST, Ulla OLSSON-STROMBERG, Daniela ŽÁČKOVÁ, Franck E NICOLINI, Han BAO, Fausto CASTAGNETTI, Elzbieta PATKOWSKA, Jiří MAYER, Klaus HIRSCHBUEHL, Helena PODGORNIK, Edyta PACZKOWSKA, Anne PARRY, Thomas ERNST, Astghik VOSKANYAN, Elzbieta SZCZEPANEK, Susanne SAUSSELE, Georg-Nikolaus FRANKE, Alexander KIANI, Edgar FABER, Stefan KRAUSE, Luis Felipe CASADO, Krzysztof LEWANDOWSKI, Matthias EDER, Peter ANHUT, Justyna GIL, Thomas SUEDHOFF, Holger HEBART, Sonja HEIBL, Markus PFIRRMANN, Andreas HOCHHAUS a Michael LAUSEKER. Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. Leukemia. London: Nature Publishing Group, 2024, roč. 38, č. 5, s. 1072-1080. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-024-02204-y.

@article{2407802,
   author = {Brioli, Annamaria and Lomaia, Elza and Fabisch, Christian and Sacha, Tomasz and Klamova, Hana and Morozova, Elena and Golos, Aleksandra and Ernst, Philipp and OlssonandStromberg, Ulla and Žáčková, Daniela and Nicolini, Franck E and Bao, Han and Castagnetti, Fausto and Patkowska, Elzbieta and Mayer, Jiří and Hirschbuehl, Klaus and Podgornik, Helena and Paczkowska, Edyta and Parry, Anne and Ernst, Thomas and Voskanyan, Astghik and Szczepanek, Elzbieta and Saussele, Susanne and Franke, GeorgandNikolaus and Kiani, Alexander and Faber, Edgar and Krause, Stefan and Casado, Luis Felipe and Lewandowski, Krzysztof and Eder, Matthias and Anhut, Peter and Gil, Justyna and Suedhoff, Thomas and Hebart, Holger and Heibl, Sonja and Pfirrmann, Markus and Hochhaus, Andreas and Lauseker, Michael},
   article_location = {London},
   article_number = {5},
   doi = {http://dx.doi.org/10.1038/s41375-024-02204-y},
   keywords = {chronic myeloid leukemia; tyrosine kinase inhibitor era},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry},
   url = {https://www.nature.com/articles/s41375-024-02204-y},
   volume = {38},
   year = {2024}
}

TY  - JOUR
ID  - 2407802
AU  - Brioli, Annamaria - Lomaia, Elza - Fabisch, Christian - Sacha, Tomasz - Klamova, Hana - Morozova, Elena - Golos, Aleksandra - Ernst, Philipp - Olsson-Stromberg, Ulla - Žáčková, Daniela - Nicolini, Franck E - Bao, Han - Castagnetti, Fausto - Patkowska, Elzbieta - Mayer, Jiří - Hirschbuehl, Klaus - Podgornik, Helena - Paczkowska, Edyta - Parry, Anne - Ernst, Thomas - Voskanyan, Astghik - Szczepanek, Elzbieta - Saussele, Susanne - Franke, Georg-Nikolaus - Kiani, Alexander - Faber, Edgar - Krause, Stefan - Casado, Luis Felipe - Lewandowski, Krzysztof - Eder, Matthias - Anhut, Peter - Gil, Justyna - Suedhoff, Thomas - Hebart, Holger - Heibl, Sonja - Pfirrmann, Markus - Hochhaus, Andreas - Lauseker, Michael
PY  - 2024
TI  - Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry
JF  - Leukemia
VL  - 38
IS  - 5
SP  - 1072-1080
EP  - 1072-1080
PB  - Nature Publishing Group
SN  - 08876924
KW  - chronic myeloid leukemia
KW  - tyrosine kinase inhibitor era
UR  - https://www.nature.com/articles/s41375-024-02204-y
N2  - Blast phase (BP) of chronic myeloid leukemia (CML) still represents an unmet clinical need with a dismal prognosis. Due to the rarity of the condition and the heterogeneity of the biology and clinical presentation, prospective trials and concise treatment recommendations are lacking. Here we present the analysis of the European LeukemiaNet Blast Phase Registry, an international collection of the clinical presentation, treatment and outcome of blast phases which had been diagnosed in CML patients after 2015. Data reveal the expected heterogeneity of the entity, lacking a clear treatment standard. Outcomes remain dismal, with a median overall survival of 23.8 months (median follow up 27.8 months). Allogeneic stem cell transplantation (alloSCT) increases the rate of deep molecular responses. De novo BP and BP evolving from a previous CML do show slightly different features, suggesting a different biology between the two entities. Data show that outside clinical trials and in a real-world setting treatment of blast phase is individualized according to disease- and patient-related characteristics, with the aim of blast clearance prior to allogeneic stem cell transplantation. AlloSCT should be offered to all patients eligible for this procedure.
ER  -

BRIOLI, Annamaria, Elza LOMAIA, Christian FABISCH, Tomasz SACHA, Hana KLAMOVA, Elena MOROZOVA, Aleksandra GOLOS, Philipp ERNST, Ulla OLSSON-STROMBERG, Daniela ŽÁČKOVÁ, Franck E NICOLINI, Han BAO, Fausto CASTAGNETTI, Elzbieta PATKOWSKA, Jiří MAYER, Klaus HIRSCHBUEHL, Helena PODGORNIK, Edyta PACZKOWSKA, Anne PARRY, Thomas ERNST, Astghik VOSKANYAN, Elzbieta SZCZEPANEK, Susanne SAUSSELE, Georg-Nikolaus FRANKE, Alexander KIANI, Edgar FABER, Stefan KRAUSE, Luis Felipe CASADO, Krzysztof LEWANDOWSKI, Matthias EDER, Peter ANHUT, Justyna GIL, Thomas SUEDHOFF, Holger HEBART, Sonja HEIBL, Markus PFIRRMANN, Andreas HOCHHAUS a Michael LAUSEKER. Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. \textit{Leukemia}. London: Nature Publishing Group, 2024, roč.~38, č.~5, s.~1072-1080. ISSN~0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-024-02204-y.

Podrobný výpis o publikaci